@article {Kratochwil237, author = {Nicole A. Kratochwil and Miriam Triyatni and Martina B. Mueller and Florian Klammers and Brian Leonard and Dan Turley and Josephine Schmaler and Aynur Ekiciler and Birgit Molitor and Isabelle Walter and Pierre-Alexis Gonsard and Charles A. Tournillac and Alexandre Durrwell and Michaela Marschmann and Russell Jones and Mohammed Ullah and Franziska Boess and Giorgio Ottaviani and Yuyan Jin and Neil J. Parrott and Stephen Fowler}, title = {Simultaneous Assessment of Clearance, Metabolism, Induction, and Drug-Drug Interaction Potential Using a Long-Term In Vitro Liver Model for a Novel Hepatitis B Virus Inhibitor}, volume = {365}, number = {2}, pages = {237--248}, year = {2018}, doi = {10.1124/jpet.117.245712}, publisher = {American Society for Pharmacology and Experimental Therapeutics}, abstract = {Long-term in vitro liver models are now widely explored for human hepatic metabolic clearance prediction, enzyme phenotyping, cross-species metabolism, comparison of low clearance drugs, and induction studies. Here, we present studies using a long-term liver model, which show how metabolism and active transport, drug-drug interactions, and enzyme induction in healthy and diseased states, such as hepatitis B virus (HBV) infection, may be assessed in a single test system to enable effective data integration for physiologically based pharmacokinetic (PBPK) modeling. The approach is exemplified in the case of (3S)-4-[[(4R)-4-(2-Chloro-4-fluorophenyl)-5-methoxycarbonyl-2-thiazol-2-yl-1,4-dihydropyrimidin-6-yl]methyl]morpholine-3-carboxylic acid RO6889678, a novel inhibitor of HBV with a complex absorption, distribution, metabolism, and excretion (ADME) profile. RO6889678 showed an intracellular enrichment of 78-fold in hepatocytes, with an apparent intrinsic clearance of 5.2 {\textmu}l/min per mg protein and uptake and biliary clearances of 2.6 and 1.6 {\textmu}l/min per mg protein, respectively. When apparent intrinsic clearance was incorporated into a PBPK model, the simulated oral human profiles were in good agreement with observed data at low doses but were underestimated at high doses due to unexpected overproportional increases in exposure with dose. In addition, the induction potential of RO6889678 on cytochrome P450 (P450) enzymes and transporters at steady state was assessed and cotreatment with ritonavir revealed a complex drug-drug interaction with concurrent P450 inhibition and moderate UDP-glucuronosyltransferase induction. Furthermore, we report on the first evaluation of in vitro pharmacokinetics studies using HBV-infected HepatoPac cocultures. Thus, long-term liver models have great potential as translational research tools exploring pharmacokinetics of novel drugs in vitro in health and disease.}, issn = {0022-3565}, URL = {https://jpet.aspetjournals.org/content/365/2/237}, eprint = {https://jpet.aspetjournals.org/content/365/2/237.full.pdf}, journal = {Journal of Pharmacology and Experimental Therapeutics} }